Articles with public access mandates - Rolando PajonLearn more
Not available anywhere: 1
The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised …
B Essink, L Chu, W Seger, E Barranco, N Le Cam, H Bennett, V Faughnan, ...
The Lancet Infectious Diseases 23 (5), 621-633, 2023
Mandates: US National Institutes of Health, US Assistant Secretary for Preparedness …
Available somewhere: 53
Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine
LR Baden, HM El Sahly, B Essink, K Kotloff, S Frey, R Novak, D Diemert, ...
New England journal of medicine 384 (5), 403-416, 2021
Mandates: US National Institutes of Health, US Department of Veterans Affairs, US …
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
PB Gilbert, DC Montefiori, AB McDermott, Y Fong, D Benkeser, W Deng, ...
Science 375 (6576), 43-50, 2022
Mandates: Bill & Melinda Gates Foundation, US National Institutes of Health, US …
Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase
HM El Sahly, LR Baden, B Essink, S Doblecki-Lewis, JM Martin, ...
New England Journal of Medicine 385 (19), 1774-1785, 2021
Mandates: US National Institutes of Health, US Department of Veterans Affairs, US …
Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
A Pegu, SE O’Connell, SD Schmidt, S O’Dell, CA Talana, L Lai, J Albert, ...
Science 373 (6561), 1372-1377, 2021
Mandates: US National Institutes of Health
SARS-CoV-2 variant B. 1.1. 7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines
X Shen, H Tang, C McDanal, K Wagh, W Fischer, J Theiler, H Yoon, D Li, ...
Cell host & microbe 29 (4), 529-539. e3, 2021
Mandates: US Department of Energy, US National Institutes of Health
Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents
K Ali, G Berman, H Zhou, W Deng, V Faughnan, M Coronado-Voges, ...
New England Journal of Medicine 385 (24), 2241-2251, 2021
Mandates: US National Institutes of Health, US Assistant Secretary for Preparedness …
SARS-CoV-2 Omicron variant neutralization after mRNA-1273 booster vaccination
R Pajon, NA Doria-Rose, X Shen, SD Schmidt, S O’Dell, C McDanal, ...
New England Journal of Medicine 386 (11), 1088-1091, 2022
Mandates: US National Institutes of Health, US Assistant Secretary for Preparedness …
Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis
A Choi, M Koch, K Wu, L Chu, LZ Ma, A Hill, N Nunna, W Huang, ...
Nature medicine 27 (11), 2025-2031, 2021
Mandates: US National Institutes of Health, US Assistant Secretary for Preparedness …
A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine
L Chu, R McPhee, W Huang, H Bennett, R Pajon, B Nestorova, B Leav, ...
Vaccine 39 (20), 2791-2799, 2021
Mandates: US Department of Energy, US National Institutes of Health, US Assistant …
Neutralization of SARS-CoV-2 variants B. 1.429 and B. 1.351
X Shen, H Tang, R Pajon, G Smith, GM Glenn, W Shi, B Korber, ...
New England Journal of Medicine 384 (24), 2352-2354, 2021
Mandates: US Department of Energy
Evaluation of mRNA-1273 Covid-19 vaccine in children 6 to 11 years of age
CB Creech, E Anderson, V Berthaud, I Yildirim, AM Atz, I Melendez Baez, ...
New England Journal of Medicine 386 (21), 2011-2023, 2022
Mandates: US National Institutes of Health, US Assistant Secretary for Preparedness …
Serum neutralizing activity of mRNA-1273 against SARS-CoV-2 variants
A Choi, M Koch, K Wu, G Dixon, J Oestreicher, H Legault, ...
Journal of virology 95 (23), 10.1128/jvi. 01313-21, 2021
Mandates: US National Institutes of Health
Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial
S Chalkias, F Eder, B Essink, S Khetan, B Nestorova, J Feng, X Chen, ...
Nature medicine 28 (11), 2388-2397, 2022
Mandates: US National Institutes of Health
Mapping SARS-CoV-2 antigenic relationships and serological responses
SH Wilks, B Mühlemann, X Shen, S Türeli, EB LeGresley, A Netzl, ...
Science 382 (6666), eadj0070, 2023
Mandates: Bill & Melinda Gates Foundation
Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates
R Pajon, PT Beernink, LH Harrison, DM Granoff
Vaccine 28 (9), 2122-2129, 2010
Mandates: US National Institutes of Health
Booster of mRNA-1273 strengthens SARS-CoV-2 Omicron neutralization
NA Doria-Rose, X Shen, SD Schmidt, S O’Dell, C McDanal, W Feng, ...
MedRxiv, 2021
Mandates: US National Institutes of Health
Evaluation of mRNA-1273 vaccine in children 6 months to 5 years of age
EJ Anderson, CB Creech, V Berthaud, A Piramzadian, KA Johnson, ...
New England Journal of Medicine 387 (18), 1673-1687, 2022
Mandates: US National Institutes of Health, US Assistant Secretary for Preparedness …
Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial
L Chu, K Vrbicky, D Montefiori, W Huang, B Nestorova, Y Chang, A Carfi, ...
Nature medicine 28 (5), 1042-1049, 2022
Mandates: US National Institutes of Health, US Assistant Secretary for Preparedness …
Preliminary analysis of safety and immunogenicity of a SARS-CoV-2 variant vaccine booster
K Wu, A Choi, M Koch, LZ Ma, A Hill, N Nunna, W Huang, J Oestreicher, ...
MedRxiv, 2021.05. 05.21256716, 2021
Mandates: US National Institutes of Health, US Assistant Secretary for Preparedness …
Publication and funding information is determined automatically by a computer program